In the last year, it looks like Pfizer has been busy raking in billions and spending many of them to acquire other companies.
In a quick search, here’s what I found about their earnings. This was a very quick search, by the way. You can find links in each section and I recommend that you follow those links and read the articles and stories for yourself, and then look deeper.
CNBC. Jan 31, 2023:
The ongoing Covid-19 pandemic propelled pharmaceutical company Pfizer’s earnings to a record $100 billion last year, almost $57 billion of which was driven by its vaccine and antiviral pill Paxlovid, the company reported Tuesday.
The vaccine accounted for $37.8 billion, up just 3% from 2021, of Pfizer’s total sales as demand for the shots slowed. But sales of its blockbuster antiviral treatment made up for that softening, surging to $18.9 billion in 2022, the first full year that Paxlovid was on the market.
- Pfizer sold $37.8 billion of its Covid vaccine last year, a small increase of 3% compared with 2021 as demand for the shots slowed.
- Sales of Paxlovid, however, surged to $18.9 billion in 2022, which was the first full year the antiviral pill was available.
- Pfizer expects its revenue to decline in 2023 by as much as 33% to a range of $67 billion to $71 billion as the world emerges from the pandemic and demand for its blockbuster Covid drugs slows.
Newsweek. Feb 2, 2023.
Pharmaceutical giant Pfizer has been accused of making an “obscene profit” from the coronavirus pandemic after it posted record revenue of more than $100 billion for 2022, a rise of 23 percent on the previous year.
The company’s COVID products Comirnaty, an mRNA vaccine and Paxlovid, an oral antiviral, accounted for over $56.7 billion of the company’s worldwide revenue. Sales of the two drugs in the U.S. alone accounted for around $19.3 billion, its January 31 financial results revealed, with the company having an estimated market share of 64 percent for the vaccine in America.
So what is Pfizer doing with all that money, now that the market for COVID products is softening? How is it diversifying its portfolio to keep the profits rolling in?
Purchasing other companies.
Acquisitions in 2022 and 2023
Seagen: “Pfizer will acquire Seagen, a global biotechnology company that discovers, develops and commercializes transformative cancer medicines, for $229 in cash per Seagen share for a total enterprise value of $43 billion.”
The Pfizer CEO announced: “Oncology continues to be the largest growth driver in global medicine, and this acquisition will enhance Pfizer’s position in this important space and contribute meaningfully to the achievement of Pfizer’s near- and long-term financial goals.”
More on Seagen from Reuters: “Pfizer on Monday struck a $43 billion deal to acquire Seagen Inc. and its targeted cancer therapies as it braces for a steep fall in COVID-19 sales and generic competition for some top-selling drugs.
“Seagen marks Pfizer’s largest purchase in a string of recent acquisitions utilizing a once-in-a-lifetime cash windfall from its COVID-19 vaccine and treatment. It will add four approved cancer therapies with combined sales of nearly $2 billion in 2022.”
Global Blood Therapeutics: “Pfizer Inc. announced today the completion of its acquisition of Global Blood Therapeutics, Inc., a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments that provide hope to underserved patient communities starting with sickle cell disease.”
Biohaven Pharmaceuticals: “Pfizer Inc. announced today the completion of its acquisition of Biohaven Pharmaceutical Holding Company Ltd., the maker of NURTEC® ODT (rimegepant), an innovative migraine therapy approved for both acute treatment and prevention of episodic migraine in adults.” Chief Business Innovation Officer for Pfizer said, “Combined with Pfizer’s global reach, this acquisition increases our potential to bring new treatment options to patients with migraine – a disease which affects over 1 billion people worldwide.”
Arena Pharmaceuticals: “Pfizer Inc. announced today the completion of its acquisition of Arena Pharmaceuticals, a clinical stage company developing innovative potential therapies for the treatment of several immuno-inflammatory diseases.”
“One of the drugs is in development for the treatment of immuno-inflammatory diseases including ulcerative colitis, Crohn’s Disease, atopic dermatitis, eosinophilic esophagitis, and alopecia areata.”
What Are These Companies Focused on Treating?
Here are the various health problems that are being addressed by these companies that have been acquired. Following each item is evidence that one of the Covid vaccines actually causes that health problem. Follow the link to the evidence. And remember, all this data was collected in a quick look. Imagine what a deep dive into this subject would find!
Ulcerative colitis (UC): “BNT162b2 [Pfizer] vaccine may have caused exacerbation of UC.”
Crohn’s Disease: “A total of 3316 individuals with IBD [irritable bowel disorder] received at least 1 COVID-19 vaccine.”
Atopic dermatitis: Definition: Atopic dermatitis (AD) is the most common type of eczema, affecting more than 9.6 million children and about 16.5 million adults in the United States.
“In addition, the exacerbation of chronic immuno-mediated dermatoses (mainly psoriasis and atopic dermatitis) and reactivations of herpes infection were reported” after Covid vaccines.
Eosinophilic esophagitis: Definition: Eosinophilic esophagitis (EoE) is an inflammation of the esophagus (the tube connecting the mouth to the stomach), caused by a specific white blood cell – the eosinophil.
“In total, we identified 16 cases…of eosinophilia without another identifiable cause occurring after vaccination with one of the COVID-19 mRNA vaccines. Of these, 13 were associated with the Pfizer vaccine (81%).”
Alopecia areata (AA): Definition: Alopecia is the medical term for bald. Areata means patchy.
“We report 5 cases of AA after COVID-19 vaccination… Three cases occurred after Moderna COVID-19 vaccine and 2 after Pfizer-BioNTech COVID-19 vaccine.”
Sickle cell: Note: People with sickle cell disease often have issues with blood clots
“A recent report in the Mediterranean Journal of Hematology and Infectious Diseases detailed 3 cases of patients with sickle cell disease (SCD) who had severe vaso-occlusive crisis (VOC) soon after receiving vaccination with the ChAdOx1 nCov-19 vaccine.”
Definitions: Vaso-occlusive crisis, a problem specific to sickle cell anemia. “A vaso-occlusive crisis occurs when the microcirculation is obstructed… causing ischemic [insufficent blood supply] injury to the organ supplied and resultant pain.” ChAdOx1 nCov-19 is the AstraZeneca vaccine.
Cancer: From a study titled: Innate immune suppression by SARS-CoV-2 mRNA vaccinations
“We also identify potential profound disturbances in regulatory control of protein synthesis and cancer surveillance. These disturbances potentially have a causal link to neurodegenerative disease, myocarditis, immune thrombocytopenia, Bell’s palsy, liver disease, impaired adaptive immunity, impaired DNA damage response and tumorigenesis.” Definition: tumorigenesis—the production or formation of tumors.
Migraines: From a study titled Headache Worsening after COVID-19 Vaccination.
“Vaccines have represented the breakthrough in the fight against COVID-19. Based on reported headache attacks after vaccination in randomized controlled trials, we focused on the effects of COVID-19 vaccine administration on the migraine population, using an online questionnaire published on Italian Facebook groups oriented to headache patients. …The main finding concerns headaches perceived by 57.60% of patients: attacks following vaccination were referred to as more severe (50.62% of patients), long-lasting (52.80% of patients) and hardwearing (49.69% of patients) compared to the usually experienced migraine attacks.”
It appears that Pfizer has been investing in companies that produce drugs that treat the very problems that their COVID vaccine and the COVID vaccines of other companies create. This is a brilliant money-making strategy but is, of course, cruelly and brutally anti-human.
A few things I’d like to note:
- Some of the connections between vaccines and these health problems were easy to find and others were buried under layers of whitewash.
- Pfizer must expect these problems to stick around for a while or they would not bother to invest in these companies.
- The acquisitions also imply that Pfizer has been aware of the adverse effects of their products for quite a while. These acquisitions don’t happen overnight.
- The FDA is 100% asleep at the wheel and not doing its job in any way, shape or form. We know why that is.
As I said earlier, this was just a very quick study. I invite you to take a deeper look for yourself. Feel free to send me anything good you find and I can add it to this post.